VALUENCE
16.7.2021 10:56:09 CEST | Business Wire | Press release
Valuence Japan Inc. (Tokyo; Susumu Muguruma, representative director and president), a member of the Valuence Group (TOKYO:9270), announced on July 1, the launch of the official version of its winning bid market price chart, available by subscription. The official version of the service has been upgraded and comes with new, useful features. Star Buyers Auction is a luxury brand goods auction service operated by Valuence Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210716005104/en/
New Features and Upgrades Reflect Partner Input
The Valuence Japan-operated Star Buyers Auction is a pre-owned luxury branded goods B2B auction and the main sales channel of the Valuence Group. Since the launch of Star Buyers Auction, the service has continued to grow in scale, adding new categories and offering new services, including online global auctions. In February 2021, Valuence Japan introduced a beta version of a market price chart subscription service for use by partners around the world. This service displays global market prices (actual winning auction bids) for a variety of goods. The company received abundant and valuable feedback from its partners regarding bidding and consignment sales, at the same time attracting an increasing number of new subscribers.
Valuence Japan added new functions to the Star Buyers Auction market price chart subscription service, incorporating feedback from partners. The company released the official upgraded version of the service on July 1. At the same time, the company will continue to look at upgrading the service based on feedback, striving to create a global reuse platform serving as an indispensable part of the purchasing and selling markets.
Official Version and Upgrades
The official version of the market price chart service now allows users to enter multiple search terms, including brand and model names. This powerful upgrade reduces time spent in search for specific products. Users may also conduct searches by transaction date range, providing a narrower view of the vast amount of transaction data available. The search results screen now displays accessories, prices, and transaction dates in either ascending or descending order. Here, users will be able to sort through information, including accessories, price ranges, and other data for multiple products. Search results draw on the more than 25,000 items sold every auction, demonstrating the vast amount of valuable market data accumulated by Star Buyers Auction.
Valuence Japan is confident that the upgraded version of this service will deliver the type of market price information needed and used by the B2B auction partners.
Star Buyers Auction Overview
A luxury brand goods auction for reuse business dealers, launched in April 2013. In April 2020, auctions were migrated to a fully online format, listing a constantly stable stream of luxury items both in quantity and quality. Listings primarily focus on watches, bags, and brand jewelry procured by the Valuence Group. Auctions are held twice monthly. Market price chart subscription service is also available for 11,000 yen per month.
Official Site: https://biz.starbuyers-global-auction.com/en/
Youtube: https://youtu.be/efUtXrO9JkE
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005104/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom